Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,077 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Database for queries of melanoma cohorts with molecular and clinical data.
Philip M, Puppel SH, Stiller M, Paschen A, Roesch A, Zaremba A, Schadendorf D, Horn S. Philip M, et al. Among authors: schadendorf d. Pigment Cell Melanoma Res. 2023 Mar;36(2):252-258. doi: 10.1111/pcmr.13075. Epub 2022 Dec 7. Pigment Cell Melanoma Res. 2023. PMID: 36382970
Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, Steinle A, Schadendorf D, Ugurel S. Paschen A, et al. Among authors: schadendorf d. Clin Cancer Res. 2009 Aug 15;15(16):5208-15. doi: 10.1158/1078-0432.CCR-09-0886. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671853
New developments in biomarkers for melanoma.
Griewank KG, Ugurel S, Schadendorf D, Paschen A. Griewank KG, et al. Among authors: schadendorf d. Curr Opin Oncol. 2013 Mar;25(2):145-51. doi: 10.1097/CCO.0b013e32835dafdf. Curr Opin Oncol. 2013. PMID: 23334230 Review.
TERT promoter mutations in familial and sporadic melanoma.
Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R. Horn S, et al. Among authors: schadendorf d. Science. 2013 Feb 22;339(6122):959-61. doi: 10.1126/science.1230062. Epub 2013 Jan 24. Science. 2013. PMID: 23348503
Vemurafenib reverses immunosuppression by myeloid derived suppressor cells.
Schilling B, Sucker A, Griewank K, Zhao F, Weide B, Görgens A, Giebel B, Schadendorf D, Paschen A. Schilling B, et al. Among authors: schadendorf d. Int J Cancer. 2013 Oct 1;133(7):1653-63. doi: 10.1002/ijc.28168. Epub 2013 Apr 13. Int J Cancer. 2013. PMID: 23526263 Free article.
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
Niessner H, Forschner A, Klumpp B, Honegger JB, Witte M, Bornemann A, Dummer R, Adam A, Bauer J, Tabatabai G, Flaherty K, Sinnberg T, Beck D, Leiter U, Mauch C, Roesch A, Weide B, Eigentler T, Schadendorf D, Garbe C, Kulms D, Quintanilla-Martinez L, Meier F. Niessner H, et al. Among authors: schadendorf d. Cancer Med. 2013 Feb;2(1):76-85. doi: 10.1002/cam4.50. Epub 2013 Feb 3. Cancer Med. 2013. PMID: 24133630 Free PMC article.
Genetic evolution of T-cell resistance in the course of melanoma progression.
Sucker A, Zhao F, Real B, Heeke C, Bielefeld N, Maβen S, Horn S, Moll I, Maltaner R, Horn PA, Schilling B, Sabbatino F, Lennerz V, Kloor M, Ferrone S, Schadendorf D, Falk CS, Griewank K, Paschen A. Sucker A, et al. Among authors: schadendorf d. Clin Cancer Res. 2014 Dec 15;20(24):6593-604. doi: 10.1158/1078-0432.CCR-14-0567. Epub 2014 Oct 7. Clin Cancer Res. 2014. PMID: 25294904 Free PMC article.
1,077 results